AI drug research firm Exscientia has delivered the first candidate molecule to its partner GlaxoSmithKline following an R&D tie-up signed in 2017.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,